Publications by authors named "Maciej Niemiec"
Article Synopsis
- The study investigates the effectiveness and safety of immunotherapy using checkpoint inhibitors for older patients (70 years and above) diagnosed with metastatic melanoma, addressing a gap in knowledge for this demographic.
- A total of 82 patients aged 70 and older were analyzed, revealing comparable median progression-free survival (PFS) and overall survival (OS) rates between older and younger patients, with a 2-year OS of 27% for the older group.
- Results indicate that despite the presence of co-morbidities, older patients can tolerate immunotherapy similarly to younger patients, suggesting that age should not prevent them from receiving this treatment.
Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) and anti-programmed death receptor-1/ligand-1 (anti-PD-1/anti-PD-L1) caused a breakthrough in oncology and significantly improved therapeutic outcomes in cancer patients. ICIs generate a specific reaction in T cells, directed against antigens on cancer cells, leading to their damage and death. Through similar or the same antigens, activated lymphocytes may also have a cytotoxic effect on healthy cells, causing development of specific adverse effects - so-called immune-related adverse events (irAEs).
View Article and Find Full Text PDFWe present a case of a 54-year-old woman treated for stage IIAE primary diffuse large B-cell lymphoma (DLBCL) of the uterine cervix. The CHOP chemotherapy regimen was started. After the diagnosis of lymphoma of DLBCL CD20+ type was confirmed, rituximab was added to the therapy.
View Article and Find Full Text PDFIntroduction: Treatment of the metastatic stage of renal cell carcinoma is specific because classical chemotherapy is not applicable here. The treatment is mainly based on molecularly targeted drugs, including inhibitors of tyrosine kinases. In many cases the therapy takes many months, and patients often report to general practitioners due to adverse events.
View Article and Find Full Text PDFBackground And Purpose: The aim of the study was to assess the results of treatment with temozolomide in patients with high-grade gliomas who no longer benefit from surgical treatment and radiotherapy.
Material And Methods: The retrospective analysis included 51 patients treated between 2001 and 2007 in the Centre of Oncology in Kraków. Glioblastoma multiforme was histologically diagnosed in 24 (47%) patients; anaplastic astrocytomas and other grade III gliomas (according to WHO classification) were diagnosed in 27 (53%) patients.